^
    over1year
    Olverembatinib Benefit Holds Up in BCR-ABL1 T315I-Mutant, TKI-Resistant CML @ASH_hematology #mpnsm #ASH22 https://t.co/d4GwbtyWaV (@OncLive)
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation
    |
    Nailike (olverembatinib)